Quoin Pharmaceuticals Reports Accountant Change and Filings

Ticker: QNRX · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1671502

Quoin Pharmaceuticals, Ltd. 8-K Filing Summary
FieldDetail
CompanyQuoin Pharmaceuticals, Ltd. (QNRX)
Form Type8-K
Filed DateMar 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: accountant-change, filings, financial-statements

TL;DR

Quoin Pharma changed accountants and filed docs. Keep an eye on financials.

AI Summary

Quoin Pharmaceuticals, Ltd. filed an 8-K on March 20, 2025, reporting changes in its certifying accountant and filing financial statements and exhibits. The report was filed as of March 20, 2025, with the earliest event reported on March 18, 2025. The company was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.

Why It Matters

Changes in a company's certifying accountant can signal shifts in financial oversight or potential concerns, while the filing of financial statements is crucial for investor transparency.

Risk Assessment

Risk Level: low — This filing is procedural, reporting standard corporate events like changes in accountants and the submission of financial documents, without indicating immediate operational or financial distress.

Key Players & Entities

  • Quoin Pharmaceuticals, Ltd. (company) — Registrant
  • Cellect Biotechnology Ltd. (company) — Former Company Name
  • Cellect Biomed Ltd. (company) — Former Company Name
  • March 18, 2025 (date) — Date of earliest event reported
  • March 20, 2025 (date) — Date of Report

FAQ

What is the primary reason for the 8-K filing by Quoin Pharmaceuticals, Ltd.?

The primary reasons for the 8-K filing are changes in the registrant's certifying accountant and the filing of financial statements and exhibits.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on March 18, 2025.

What were Quoin Pharmaceuticals, Ltd.'s former company names?

Quoin Pharmaceuticals, Ltd. was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.

What is the SEC file number for Quoin Pharmaceuticals, Ltd.'s 8-K filing?

The SEC file number for Quoin Pharmaceuticals, Ltd.'s 8-K filing is 001-37846.

What is the principal executive office address for Quoin Pharmaceuticals, Ltd.?

The principal executive office address for Quoin Pharmaceuticals, Ltd. is 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Quoin Pharmaceuticals, Ltd. (QNRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.